Ozuriftamab vedotin

DB17422InvestigationalProtein Based Therapies

Ozuriftamab vedotin: Overview.

Mechanism: Pharmacologically active on Tyrosine-protein kinase transmembrane receptor ROR2
Curator reviewed
Also known as: Ba-302 conjugated to monomethyl auristatin e
Code names: BA-3021 · CAB-ROR2-ADC (BA-3021)

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ozuriftamab vedotin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.